相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis
Nicholas Latimer et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Information on cost-effectiveness: An essential product of a national comparative effectiveness program
Neil Kirschner et al.
ANNALS OF INTERNAL MEDICINE (2008)
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib
E. Setakis et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
T. -P. van Staa et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands
Maiwenn J. Al et al.
VALUE IN HEALTH (2008)
The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks
Tjeerd-Peter van Staa et al.
VALUE IN HEALTH (2007)
Randomized trials with concurrent economic evaluations reported unrepresentatively large clinical effect sizes
Simon Gilbody et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2007)
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Loren Laine et al.
LANCET (2007)
External validity: the neglected dimension in evidence ranking
Navindra Persaud et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2006)
Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
RA Elliott et al.
RHEUMATOLOGY (2006)
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study
G Singh et al.
AMERICAN JOURNAL OF MEDICINE (2006)
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis
DR Ramey et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Minimizing complications from nonsteroidal antiinflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups
BMR Spiegel et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis
HR Yun et al.
RHEUMATOLOGY INTERNATIONAL (2005)
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration
M Schaefer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: A decision analysis
HK Choi et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
ME Farkouh et al.
LANCET (2004)
The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal
BMR Spiegel et al.
GASTROENTEROLOGY (2004)
National Institute for Clinical Excellence and its value judgments
MD Rawlins et al.
BRITISH MEDICAL JOURNAL (2004)
Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study
M Mamdani et al.
BRITISH MEDICAL JOURNAL (2004)
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced lay non-steroidal anti-inflammatory drugs: systematic review
L Hooper et al.
BRITISH MEDICAL JOURNAL (2004)
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis
DJ Watson et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK
A Moore et al.
PHARMACOECONOMICS (2004)
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis - A randomized, controlled trial
JR Lisse et al.
ANNALS OF INTERNAL MEDICINE (2003)
Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease
KKC Lee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis
A Maetzel et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis
BMR Spiegel et al.
ANNALS OF INTERNAL MEDICINE (2003)
The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis
CC Kamath et al.
VALUE IN HEALTH (2003)
Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis
SC Bae et al.
RHEUMATOLOGY (2003)
Arthritis treatment in Hong Kong - cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents
JHS You et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs - The use of a nomogram in cost-effectiveness analysis
HB El-Serag et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: A decision analysis
AM Fendrick et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis
JM Pellissier et al.
CLINICAL THERAPEUTICS (2001)
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis
TA Burke et al.
PHARMACOECONOMICS (2001)
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland
JVM Chancellor et al.
PHARMACOECONOMICS (2001)
An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada
RA Zabinski et al.
PHARMACOECONOMICS (2001)
Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis - Ontario ministry of health perspective
JK Marshall et al.
PHARMACOECONOMICS (2001)
Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway
P Svarvar et al.
RHEUMATOLOGY (2000)
Overview of the Arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib
D Pettitt et al.
RHEUMATOLOGY (2000)
The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis
U Haglund et al.
RHEUMATOLOGY (2000)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial
FE Silverstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
